Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 1 | 37 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT07644702 | WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial Participation for Rural and Low Income Women | terminated | N/A | 1 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01039922 | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland(SwissNET) | terminated | — | 1,245 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | terminated | Phase 3 | 739 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT01029873 | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 22 | Altor BioScienceINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 | clinicaltrials |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 32 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 429 | GenmabINDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT04947618 | Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim(DVR-Lym-Nim) | terminated | — | 136 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | terminated | Phase 1 | 23 | GenmabINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | terminated | Phase 3 | 595 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 8, 2026 | clinicaltrials |
| NCT06039384 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | terminated | Phase 1 | 6 | Incyte CorporationINDUSTRY | 4 | Sep 8, 2026 | clinicaltrials |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics(CHARGE) | terminated | Phase 1 | 12 | University of UtahOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 1 | 41 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT03145857 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use | terminated | Phase 1 / Phase 2 | 634 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | terminated | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | terminated | Phase 4 | 10 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors | terminated | N/A | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(VERSATILE-003) | terminated | Phase 3 | 12 | PDS Biotechnology Corp.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | terminated | Early Phase 1 | 1 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02625961 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) | terminated | Phase 2 | 296 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 31, 2026 | clinicaltrials |
| NCT04249843 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | terminated | Phase 1 | 109 | MapKure, LLCINDUSTRY | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05458960 | Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate(BASICS) | terminated | N/A | 3 | Washington University School of MedicineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06438588 | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial | terminated | N/A | 2 | Mayo ClinicOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma | terminated | Phase 1 | 5 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 | terminated | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06171178 | A Study of ASP1012 in Adults With Solid Tumors | terminated | Phase 1 | 15 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | terminated | Phase 2 | 41 | Hoffmann-La RocheINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | terminated | Phase 2 | 18 | University of WashingtonOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 55 | AmgenINDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT01216371 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)(SMAT) | terminated | Phase 2 | 60 | Association of Urologic Oncology (AUO)OTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | terminated | Early Phase 1 | 12 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05718219 | Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors | terminated | Phase 1 | 49 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03184753 | Genetically Modified T Cells Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03185468 | Intervention of Bladder Cancer by CAR-T | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03535246 | Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials